Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Document type

Book part

Version

Published version

Publication date

Publication license

(c) Research Signpost, 2018
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/128109

Development of hybrid compounds to tackle Alzheimer’s disease

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

Alzheimer’s disease (AD) is the main neurodegenerative disorder worldwide. Its pathogenesis involves a network where various mechanisms are interconnected. This complex pathological network makes it extremely challenging to find an efficacious treatment. Herein, we give an overview on the design of the so-called multi-target-directed ligands, i.e. compounds that concurrently hit several key pathogenic factors within the network, as a realistic option to tackle AD, with a particular emphasis on some structural classes of multitarget hybrids recently developed in our group.

Description

Podeu consultar el llibre complet a: http://hdl.handle.net/2445/128014

Citation

Citation

MUÑOZ-TORRERO LÓPEZ-IBARRA, Diego and PÉREZ AREALES, Francisco Javier. Development of hybrid compounds to tackle Alzheimer’s disease. Recent Advances in Pharmaceutical Sciences VIII. 2018. Vol. Editors: Diego Muñoz-Torrero, num. ISBN: 978-81-308-0579-5, pags. 43-58. [consulted: 8 of August of 2026]. Available at: https://hdl.handle.net/2445/128109

Export metadata

JSON - METS

Share record